At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Fish Oil +3 moredietary
Likely dose
Not stated in record
Key inclusion· 4
- ✓Diagnosis of probable Alzheimer's Disease or mild cognitive impairment
- ✓Mini Mental State Examination (MMSE) score between 18 and 26
- ✓Clinical Dementia Rating (CDR) of 0.5 or 1.0
- ✓Fluent in English
Key exclusion· 7
- ✕Use of lipid lowering medications
- ✕Consumption of fish more than twice a week
- ✕Use of omega and alpha lipoic acid supplements
- ✕Use of systemic corticosteroids, neuroleptics, anti-Parkinsonian agents, or narcotic analgesics
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating Fish Oil, Lipoic Acid, and 2 other interventions for Alzheimer's Disease and 4 related conditions. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effect of fish oil and the antioxidant alpha lipoic acid on factors in the blood that are associated with the progression of Alzheimer's Disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Oxidative Stress, Dementia, Hyperlipidemia, Inflammation
CountriesUnited States
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2004
First PostedAug 2004
Primary CompletionJan 2006
Study CompletionAug 2007
TodayJul 2026
First PostedAug 26, 2004
Enrollment StartApr 1, 2004
Primary CompletionJan 3, 2006
Study CompletionAug 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 21.8 years ago
Interventions
Fish Oildietary
Fish oil capsule
Lipoic Aciddietary
Lipoic acid capsule
Fish Oil Placeboother
Soybean oil placebo capsule
Lipoic Acid Placeboother
Lipoic acid (LA) placebo capsule containing no LA